Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in Refractory Primary Immune Thrombocytopenia
NCT06799611Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gamgertamig in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Efficacy of CM336 at 12 weeks and Safety of CM336 at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06799611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799611.